From the 1Palacios Institute of Women’s Health and Medicine, Madrid, Spain; 2Service of Obstetrics and Gynecology, Hospital Universitario de Cruces, Baracaldo, Spain; and 3Medical Unit, Pfizer SLU, Madrid, Spain.
Received October 5, 2012; revised and accepted November 29, 2012.
Funding/support: This study was sponsored by Laboratorios Pfizer España (Madrid, Spain). Editorial assistance provided by Danielle Turner (Prism Ideas, Nantwich, UK) was funded by Pfizer Spain.
Financial disclosure/conflicts of interest: J.C.P. and S.F.d.C. are current employees of Pfizer. S.P. has served as symposium speaker and/or advisory board member for Servier, Pfizer, Pierre-Fabre, Bayer Schering Pharma, GSK, and Amgen, and has received research grants and/or consulting fees from Pfizer, Servier, Amgen, Bayer Schering Pharma, and Teva. J.L.N.B. declares no conflicts of interest.
Address correspondence to: Santiago Palacios, MD, Instituto Palacios, Salud y Medicina de la Mujer, Calle Antonio Acuña, 9, 28009 Madrid, Spain. E-mail: [email protected]